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KEY POINTS
 Total-body PET opens a new diagnostic paradigm with prospects for personalized disease treat-
ment, yet the high cost of the current crystal-based PET technology limits dissemination of total-
body PET in hospitals and even in the research clinics.
 The J-PET tomography system is based on axially arranged low-cost plastic scintillator strips. It
constitutes a realistic cost-effective solution of a total-body PET for broad clinical applications.
 High sensitivity of total-body J-PET and triggerless data acquisition enable multiphoton imaging,
opening possibilities for multitracer and positronium imaging, thus promising quantitative enhance-
ment of specificity in cancer and inflammatory diseases assessment.
 An example of dual tracer analysis, becoming possible with total-body J-PET system, could be a
concurrent application of Food and Drug Administration–approved 82Rb-Chloride and [18F]FDG, al-
lowing simultaneous assessment of myocardium metabolic rate and perfusion of the cardiovascu-
lar system.INTRODUCTION
As modern medicine advances toward personal-
ized treatment of patients, it requires highly spe-
cific and sensitive tests to diagnose disease. The
advent of total-body PET (TB-PET) systems1–6
opens new perspectives for the precision medi-
cine enabling detection of pathologies on a molec-
ular level in the whole patient body simultaneously,
before they lead to the functional or structural ab-
normalities.7,8 TB-PET imaging creates a new
paradigm for precision medicine, yet not fully
exploited, enabling simultaneous imaging of meta-
bolism rate in close and distant organs, reducing
drastically the whole-body scan time or the dose
delivered by the radiopharmaceutical agent (by a
factor of approximately 40 with respect to typical
current clinical PET systems).3 Introduction ofMarian Smoluchowski Institute of Physics, Jagiellonian Un
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ND license (http://creativecommons.org/licenses/by-nc-ndTB-PETs extends the PET application to diagnosis
of a wider group of patients (eg, children and preg-
nant women) and systemic diseases, as for
example, autoimmune diseases, cardiovascular
diseases, or active rheumatoid diseases8–10 by
simultaneous multiorgan kinetic modeling,
currently not possible with the w25 cm axial
filed-of-view scanners.11,12 Kinetic model-based
parametric imaging may also deliver additional
complementary diagnostic information to that
available from standard static standardized up-
take value (SUV) images.13–15
However, introduction of the TB-PET scanners
in the common clinical practice encounters chal-
lenges of the high cost, estimated to approxi-
mately $10 million or more for a single TB-PET
system built based on the current technologyiversity, ul. S. Lojasiewicza 11, Kraków 30-348, Poland
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Moskal & Stępien440using crystal scintillators.4 High price is a serious
barrier factor in using this device not only in hospi-
tal facilities but even in medical research clinics.
Therefore, there is a need for new technical so-
lution that would enable to substantially decrease
the cost of the extended axial field-of-view
(AFOV) PET, where approximately half of the cost
is in scintillators, and the other half of the costs
is in silicon photomultipliers (SiPM) and
electronics.16
The ongoing investigations aiming at cost
reduction focuses on the possibilities of (1) scintil-
lator thickness reduction17; (2) sparse detector
configurations18,19; and (3) application of BGO
crystals20,21 with Cherenkov light readout for the
improved timing properties.22–25
The reduction of detector thickness decreases
the sensitivity approximately as a square of the
reduction thickness coefficient, whereas the cost
of scintillators decreases only linearly without
reducing the costs of electronics. Similarly, in the
sparse configuration, the sensitivity drops as
square of the decrease of the number of detector
components.18 An application of BGO crystals
may reduce costs of the scintillators by a factor 2
to 316; however, at the same time the costs may in-
crease due to the increased requirements and
complications for the of readout electronics
needed for taking advantage of both scintillation
and Cherenkov light.
Therefore, it is claimed that only a spectacular
decrease in the price, while maintaining the key
parameters such as total-body dynamic/kinetic
imaging, will accelerate the dissemination process
of the TB-PET imaging.26 In general it is also
important to decrease the costs of the whole diag-
nostic process, which includes not only PET imag-
ing enabling detection of the presence of diseased
tissues based on SUV, but also histologic assess-
ments of tissues requiring biopsies for distinguish-
ing among the inflammatory, infected, and
cancerous tissues and for evaluating the grade of
cancer malignancy.
Therefore, the effective translation of TB-PET for
wide use in clinics, in view of the precision diag-
nosis tailored to the individual patient, requires sig-
nificant decrease of costs of the TB-PET
construction with respect to the pioneering EX-
PLORER PET technology and an increase of spec-
ificity in cancer and inflammatory diseases
assessment.
In this article, we discuss the principle of opera-
tion of the new Jagiellonian-PET (J-PET)aThe Netherlands has the tallest people in the world, wh
bmj.com/content/90/8/807).tomography system developed at the Jagiellonian
University, Cracow, Poland, based on axially ar-
ranged low-cost plastic scintillator strips, as con-
trasted with the current PET scanners with
radially arranged expensive crystal blocks. J-PET
enables cost-effective construction of PET with
long AFOV, up to 2.5 m and more, which would
enable high sensitivity imaging of the whole human
body, with high and uniform sensitivity over the
whole patient from the brain to the feet. Imaging
with such a large AFOV would open new perspec-
tive for diagnosis of diseases affecting the body
and brain simultaneously. J-PET may be con-
structed as a modular, light and portable TB-
PET, enabling reconfiguration of the tomographic
volume, which may help to extend PET diagnosis
further by including patients who cannot be exam-
ined with the standard PET due to factors such as
obesity or claustrophobia.
Further on, we discuss the properties of the eco-
nomic total-body J-PET (TB-J-PET), and its pros-
pects for performing both the simultaneous
multitracer imaging and positronium imaging. The
newly proposed positronium imaging is being
developed based on properties of positronium
atoms produced in the intramolecular voids in
the patient’s cells during the routine PET diag-
nosis,27–30 and it is promising for enhancing the
specificity of cancer and inflammatory diseases
assessment in TB-PET diagnostics.PROSPECTS FOR TOTAL-BODY PET IMAGING
WITH PLASTIC SCINTILLATORS
The J-PET tomography scanner is constructed
from plastic scintillator strips read out at both
ends by matrices of SiPM. Schematic view of the
axial cross-section of the scanner is shown in
Fig. 1, whereas the left panel of Fig. 2 presents a
perspective view. The position and time of the
interaction of annihilation photons is determined
by measurement of the times of scintillation light
signals arrivals to the edges of the scintillators.31
Light attenuation by plastic scintillators is by
more than 1 order of magnitude lower than in the
crystal scintillators, and that enables effective
light transport even in strips of a few meters’
length (for example, attenuation length for BC-
408 plastic scintillator amounts to 380 cm
compared with approximately 21 cm to 40 cm
for the LYSO crystal).32–34 The signals from SiPMs
are probed in the voltage domain with the time ac-
curacy of approximately 20 ps by newly developedere the average height of men is 1.83 m (https://adc.
Fig. 1. Schematic view of the axial cross section of the J-PET tomograph composed of the 2 detection layers. Left
and right panels illustrate the cases of J-PETwith 25 cm and 250 cm AFOV and the 183-cm-tall patient.a The single
detection module consists of a scintillator strip read out by two SiPM matrices. The cross section of the plastics
strips designed for the TB-J-PET is 6 mm  30 mm. Here it is presented not to scale. Solid and dashed arrows indi-
cate exemplary lines of response (LOR) originating from e1e annihilation. The interaction distance from the cen-
ter of the scintillator is determined by the difference in times the two signals reach both ends of the scintillator
strip. The position along the LOR is determined from time difference measured between two strips. In practice,
more advanced methods of hit-time and hit-position were developed, which take advantage of the variation of
the signal shape as a function of the hit-position.39,40 Superimposed charts indicate the sensitivity (in arbitrary
units) along the AFOV. It was calculated using the formula described in reference.29 The presented sensitivity in-
cludes also the attenuation of annihilation photons in the patient. The attenuation in the patient flattens the
sensitivity inside the long AFOV scanner. The value of sensitivity is given in arbitrary units, however the values
in the left and right figures are shown in the same scale.
Fig. 2. (Left) Perspective view of the design of two-layer TB-J-PET scanner. Each layer consists of 24 modules each
including 16 scintillator strips with cross-section of 6 mm  30 mm. (Right) Photograph of the single-layer (with
50 cm AFOV) modular J-PET prototype with superimposed representations of electron-positron annihilation in
the patient’s body for 2 and 3 photon events (red solid arrows) and the associated prompt gamma rays (blue
dashed arrows) emitted by the b1g radionuclide such as for example, 44Sc or 82Rb. The single-layer J-PET proto-
type with AFOV 5 50 cm weighs only approximately 60 kg. It consists of 24 modules each built from plastic scin-
tillator strips (black) read out at both ends by SiPMs equipped with the dedicated front-end and digitizing
electronics visible in the foreground.35,36
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novel triggerless and reconfigurable data acquisi-
tion system.36 The readout data are streamed to
the Central Controller Module and then to a per-
manent storage.36 For data processing and simu-
lations, a dedicated software framework was
developed.37 The hit-position and hit-time are
reconstructed by the dedicated reconstruction
methods based on the compressing sensing the-
ory38 and the library of synchronized model
signals.39Sensitivity Gain
Plastic scintillators (1.02–1.06 g/cm3)32,41 are
approximately 7 times less dense than LYSO crys-
tals (7.0–7.4 g/cm3)42 and hence less effective for
the registration of annihilation photons. However,
the axial arrangement of plastic strips with the
SiPM readout at the ends provides compensation
for the lower registration efficiency by application
of multilayer geometry with concentric detector
layers,43 as is visualized in Figs. 1 and 2 (left).
The overall imaging sensitivity depends on the
geometric acceptance of the detector, efficiency
of the registration of annihilation photons, effi-
ciency of the selection of events contributing toFig. 3. Sensitivity gain with respect to the 20 cm AFOV LYS
object), single organ (L5 10 cm object), brain with torso (L
object). Blue dotted line shows gain equal to unity. Sensit
tion of image forming events as well as attenuation of pho
and 200 cm long). Results as a function of the axial lengt
layers) PET detectors are shown. The meaning of line type
indicate results for the LYSO and plastic scintillators, respec
2g annihilation photons imaging. (Right) The sensitivity fo
the sensitivity of the triple-coincidence 2g 1 prompt positr
obtained for the total-body imaging (for source of L5 200
energy of the prompt gamma of 1157 keV as emitted bythe PET image formation, and on the attenuation
of photons in the imaged object/patient. Annihila-
tion photons emitted at small angles to the cylinder
axis (dashed LOR in Fig. 1, right) are strongly
attenuated in the patient body and effectively the
sensitivity for registration and selection of image
forming events saturates at approximately 50 cm
from the tomograph edges, as indicated by the
blue line in the right panel of Fig. 1, instead of
growing almost linearly toward the detector center
as is in the case of short AFOV systems, as indi-
cated in the left panel of Fig. 1. The solid and
dashed lines in Fig. 1 indicate examples of a
moderately and very oblique lines-of-response,
respectively.
To quantitatively estimate the gain in the scan-
ner sensitivity with the extension of the AFOV and
to compare the sensitivity gains between the
crystal and plastic based scanners, we per-
formed calculations under the assumption that
the compared scanners are in the form of a cylin-
der with the diameter of 80 cm and thickness of
1.81 cm (LYSO) and 6 cm (2 layers of plastic scin-
tillators with 3-cm thickness each). In the left
panel of Fig. 3 we present obtained results taking
into account attenuation of photons in the bodyO PET (indicated with blue) for a small lesion (L 5 1 cm
5 100 cm long object) and the total body (200 cm long
ivity includes the probability of registration and selec-
tons in the body (water phantom with 20 cm diameter
h for LYSO (1.81 cm thick) and plastic (two 3-cm-thick
s is explained in the legends. The red and black colors
tively. (Left) Results of sensitivity gain for the standard
r the standard 2g imaging of the SUV is compared to
onium imaging.27–29 In the right panel only the results
cm) are shown. Calculations were performed assuming
the 44Sc isotope.44
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as a function of the angle under which the photon
is entering the detector. The attenuation was esti-
mated approximating the body with a water
phantom of 20 cm diameter and 200 cm long.
For the whole-body scan (estimated for the
200-cm-long object) the sensitivity for the
200 cm AFOV scanner, with respect to
the 20 cm AFOV PET, is enhanced by a factor of
approximately 46 for the LYSO based and by a
factor of approximately 27 for the plastic based
TB-J-PET scanner, respectively. The gain for
brain plus torso imaging (approximated by a
100-cm-long object) saturates for the AFOV of
approximately 150 cm, and increases by a factor
of approximately 28 for the LYSO PET and by a
factor of 15 for the plastic PET. In case of the sin-
gle organ or a lesion (short 10 cm or 1 cm objects)
the gain is already saturated for systems with
70 cm AFOV and reaches values of approximately
3.8 and 2.3 (for the 10-cm object) and 3.0 and 1.8
(for the 1 cm object) for LYSO and plastic PET,
respectively.National Electrical Manufacturers Association
Characteristics: Spatial Resolution, Noise
Equivalent Count Rate, Sensitivity and Scatter
Fraction
The spatial resolution, sensitivity, scatter fraction
and noise equivalent count rate (NECR) for the
J-PET were estimated45 using GATE simulation
software,46 following the National Electrical Manu-
facturers Association (NEMA) NU 2 to 2012
standards.
For a strip length of 100 cm with cross-section
of 4 mm  20 mm and an additional layer of wave-
length shifter as the readout,47 the point spread
function (PSF) in the center of the scanner is equal
to 3 mm (radial, tangential) and 6 mm (axial). For
the double layer geometry, the NECR peak of
300 kcps is reached at 40 kBq/mL activity concen-
tration and the sensitivity at the center amounts to
14.9 cps/kBq. Whereas for the TB-J-PET with
AFOV of 200 cm and a scintillators with cross-
section of 6 mm  30 mm, the PSF is estimated
to 4.9 mm (radial, tangential) and 7 mm (axial),
the NECR peak of 600 kcps is reached at 25
kBq/mL activity concentration, and the sensitivity
at the center amounts to 38 cps/kBq. The scatter
fraction is estimated to approximately 35%. These
values can be compared with PSF of 4 mm and
3 mm, the NECR of 1435 kcps and 1000 kcps,
sensitivity at the center of 191.5 cps/kBq and
55 cps/kBq and scatter fraction of 35.8% and
32% for uEXPLORER16 and Penn PET EX-
PLORER,2 respectively.Multiphoton Imaging
High sensitivity of TB-PET scanners opens oppor-
tunities for application in PET scans of events with
the emission of 3 or more photons. The triggerless
data acquisition system of the J-PET tomograph36
enables detection of all events including multi-
photon annihilations and prompt gammas, not
restricted to the standard double annihilation pho-
tons coincidences as it is in the current PET scan-
ners. Triggerless mode opens the possibility for
flexible selection of events at the software level.37
This may include selection of double, triple and in
general multicoincidence events. In particular it
enables registration and identification of 2 (e1e
/ 2g) and 3 photon (e1e / 3g) annihilations,
as well as prompt gamma emitted in case of
some isotopes referred to as b1g emitters, such
as for example, 10C, 14O, 22Na, 34Cl, 44Sc, 48V,
52Mn, 55Co, 60Cu, 66Ga, 69Ge, 72As, 76Br, 82Rb,
86Y, 94Tc, 110In, 124I.44 Some examples of multi-
photon events are shown pictorially in the right
panel of Fig. 2. After emission of positron the
b1g emitters change into the daughter nucleus in
an excited state. The daughter nucleus subse-
quently de-excites through emission of 1 or
several gamma quanta. For example, in the case
of Scandium the reaction chain is as follows:
44Sc / 44Ca* e1 v / 44Ca g e1 v, where v de-
notes neutrino that escapes from the body
undetected.
In the current PET imaging procedures, prompt
gammas and e1e / 3g annihilations constitute
a source of unwanted background. In the body a
fraction of 3g annihilation events constitutes
approximately 0.5% only28; however, prompt
gamma may accompany almost each annihilation
as it is in the case of for example, 44Sc radionu-
clide.44 However, these multiphoton coincidences
may be useful for diagnosis.28 Capability of J-PET
to register and identify the signals from prompt
gammas and from 2g and 3g annihilations allows
for tagging the events originating from various iso-
topes. This information enables classification of
registered events according to the radiotracer,
and hence enables diagnosis with 2 or more
tracers simultaneously during single PET examina-
tion.48 Therefore, in case of the b1g emitters, an
additional prompt gamma may be used not only
for improving the spatial resolution by combining
2g PET with the various types of Compton cam-
eras for the registration of the prompt gamma as
discussed, for example, in Refs.49–53, but it may
also be used for the simultaneous multitracer im-
aging48 and for the newly developed positronium
lifetime imaging, which is a promising approach
for the in vivo assessment of tissue pathology.27–29
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with Total-Body Jagiellonian-PET
Despite potential advantage in PET imaging, espe-
cially in TB-PET, and broad accessibility of suit-
able tracers, the b-emitters application is still
limited, and to date only a few clinical trials have
been conducted. The summary of published re-
sults of the preclinical and clinical studies is pre-
sented in Table 1. Among the previously listed
18 isotopes, only one is approved by the Food
and Drug Administration (FDA) (82Rb) and only 2
(44Sc and 124I) are clinically applied and few of
them were tested preclinically.54
The trivalent b-emitters as 44Sc, 66Ga, and
monovalent 124I are especially promising because
they
i. Can be delivered by the same class of chela-
tors or carries as their commonly used ana-
logues (isotopes): DOTA,61 IMP,58 PIB,71
NOTA,62 PSMA-61767Table 1
Summary of 44Sc, 66 Ga and 124I labeled tracers propo
Cell/Tissue Molecular
Characteristics Targets
Mutations or genome
instability
CAIX mutEGFR (de2
Inducing angiogenesis Integrin aVb3
CD105
Activating motility and
mobility
Integrin aVb3
CD44v6
Expressing specific surface
antigens
SSTR2
PSMA
HER2
CEA
Abbreviations: CAIX, carbonic anhydrase IX, enzyme expressed
endoglin, surface glycoprotein identified as angiogenesis regu
promotes cell adhesion and binds vascular endothelial grow
chimeric antiCAIX monoclonal antibody, girentuximab; cRGDfK
tegrin binding; DOTA, 1,4,7,10-Tetraazacyclododecane- N,N0,N
tetraxeten; DOTATATE, compound containing 3-tyrosine-octre
nyloalanine-3-tyrosine-octreotide and DOTA; EGFR, epidermal
tin 2 receptor, receptor tyrosine-protein kinase erbB-2, also kn
MCC-Lys(MCC)-Lys(X)-d-Tyr-d-Lys(X)-OH peptide, bifunctional
body; NOTA, 1,4,7-triazacyclononane-1,4,7-triacetic acid, chel
brane antigen; SSTR2, somatostatin receptor type 2; TRC1
affibody molecule of a small (6–7 kDa) protein based on the Z
a Clinical trials.ii. Can be attached to tracers approved in clinical
trials: PSMA-617,68,74 Herceptin (trastuzu-
mab),70 cetuximab75
iii. Can recognize the same targets: EGFR58 HER2
44Sc-DOTA-ZHER2:342,72– CAIX,55,56 Integrin
aVb3,
59 PSMA,69 SST2R64
iv. Can be used in dual analysis with 2 radio-
tracers “pairs”: 124I-trastuzumab/18F-FDG70
This unique feature of the aforementioned radio-
nuclides over the standard 2g radionuclides,
which emit additional prompt g (eg, 44Sc, 66 Ga,
82Rb, 124I) provides another rationale for the appli-
cation of the TB-PET concept.
These radiotracers can be used in the TB-PET
simultaneously and complementarily with for
example, FDG to shorten the time between dosing
of a radiopharmaceutical and a PET scan, which
would reduce a diagnostic window, optimize the
uptake and clearance of each radiotracer and
minimize the risk of radiopharmaceuticals decay.sed for PET cancer imaging
Tracers (Preclinical and Clinical Studies)
-7) 124I-cG250a,55–57
124I-IMP-R4-ch80658
66Ga-DOTA-E[c(RGDfK)]259
44Sc-DOTA-RGD60
44Sc-DOTA/NODAGA-RGD61
66Ga-NOTA-GO-TRC10562
66Ga-DOTA-E[c(RGDfK)]259
44Sc-DOTA-RGD60
44Sc-DOTA/NODAGA-RGD61
124I-cMAb U3663
44Sc-DOTATOCa,64,65
124I-J59166
66Ga-PSMA-61767]
44gSc-PSMA-61768,69,a
124I-trastuzumab70,a
124I-PIB-ZHER2:34271
44Sc-DOTA-ZHER2:34272
124I anti-CEA mAbs (cT84.66)73
in the cell membrane of clear cell renal carcinoma; CD105,
lator; CD44v6, type I transmembrane glycoprotein, which
th factor (VEGF); CEA, Carcinoembryonic antigen; cG250,
, cyclo(Arg-Gly-Asp-Phe-Lys) peptide, motif specific for in-
0 0,N0 0 0- tetraacetic acid, bifunctional chelator also known as
otate and DOTA; DOTATOC, compound containing 1-phe-
growth factor receptor; GO, graphen oxide; HER2, hercep-
own as CD340, binding herceptin (trastuzumab); IMP-R4,
chelator; J591, humanized anti-PSMA monoclonal anti-
ator; PIB, p-iodobenzoate; PSMA, prostate-specific mem-
05, chimeric anti-CD105 monoclonal antibody; ZHER2,
domain (58 a.a.) derived from staphylococcal protein A
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application that became possible with TB-PET, is
the FDA-approved 82Rb-Chloride, which when
applied concurrently with [18F] fludeoxyglucose
(FDG) would enable simultaneous assessment of
metabolic rate and perfusion, mainly in the cardio-
vascular system.54,76 This would allow to assess
coronary arteries’ occlusion and myocardium
necrotic zone, as a perfusion (oxygen supply)
and viability (oxygen consumption) synchronized
tests.
Another example worth clinical trials, becoming
possible with TB-PET, could be an early diagnos-
tics of neuroendocrine and HER2-positive tumors
via simultaneous applications of radiopharmaceu-
ticals labeled with 2 different radionuclides, 44Sc
and 18F, allowing for monitoring of the cancer re-
ceptor system (eg, using 44Sc-DOTATE) end its
metabolic activity (eg, using [18F]FDG) at the
same time.Positronium Imaging
One of the examples of multiphoton imaging is the
recently proposed positronium mean lifetime to-
mography,27–30 which can deliver information
complementary to the currently used SUV-based
parameters.77 During the PET imaging, a positron
emitted by the radionuclide annihilates with the
electron in the patient’s body, directly or via forma-
tion of the metastable positronium atom. In the hu-
man body, positronium atoms are formed in up to
approximately 40% of cases of positron-electron
annihilations.78,79 Positronium is an atom built
from an electron and a positron (anti-electron). It
is not stable but annihilates with emission of pho-
tons. In a quarter of the cases it appears as a
short-lived (125 ps) para-positronium and in
three-quarters of cases as ortho-positronium
with mean lifetime in the vacuum of 142 ns. In
the tissue ortho-positronium mean lifetime
strongly depends on the size of intramolecular
voids (free volumes between atoms), whereas its
formation probability depends on the voids con-
centration (Fig. 4). In the body, the mean lifetime
of ortho-positronium varies from approximately
1.8 ns in pure water to approximately 4 ns in hu-
man skin.80 Moreover, both formation probability
and mean lifetime depend on the concentration
of the bio-fluids and bio-active molecules81,82
and the mean lifetime can be established in the hu-
man body with the precision of approximately
20 ps.29
There are investigations demonstrating differ-
ences between normal and cancerous cells with
changes of the positronium lifetime during dy-
namic processes undergoing in model and livingbiological systems.79–81,85–95 Therefore, positro-
nium may be used as a sensor of the surrounding
tissue environment, and imaging of its properties
inside the patient body may serve as additional
diagnostic indicator. In general, positronium im-
aging can be defined as a method for the
position-sensitive reconstruction of positronium
properties (such as mean lifetime, formation
probability, and 3g/2g rate ratio) within the
imaged object.27–30 Imaging of positronium life-
time and its formation probability requires appli-
cations of isotopes emitting prompt gamma,
while 3g/2g rate ratio is accessible with all kinds
of b1 emitters.96
In case of the mean lifetime positronium im-
age, registration of the prompt gamma is used
to determine the time of the emission of the posi-
tron (which is within tens of picoseconds equal
to the time of the formation of the positronium
atom) and the registration of annihilation photons
is used for the determination of the position and
time of the positronium annihilation.28,29 The
most effective way of the positronium mean life-
time image reconstruction is based on the regis-
tration of annihilations of ortho-positronium into
2 photons, which may occur in the tissue due
to the pick-off84 and conversion pro-
cesses82,97,98 and that is approximately 70 times
more frequent than annihilation into 3 pho-
tons.28,29 In this case, the back-to-back photons
are used to reconstruct the decay time and
decay position of ortho-positronium atom on an
event-by-event basis. Reconstruction of the
time difference distribution between annihilation
and the emission of the positron enables to
determine the positronium’s mean lifetime for
each image voxel.29
Time resolution of positronium imaging depends
predominantly on the statistics of events recon-
structed in the image voxel whereas the spatial
resolution depends mainly on the PET time resolu-
tion.29 Current clinical time of flight (TOF)-PETs12
achieve down to 210 ps and small laboratory
type detectors reach CRT of even 30 ps equivalent
to position resolution of 4.5 mm along the line of
response.99 Therefore, with the continuous
improvement of the time resolution25,100 it may
become feasible in not so distant future to recon-
struct positronium image directly as a density dis-
tribution of annihilation points.29,30 Resent
simulation studies29 indicate that the PSF of posi-
tronium image equals to approximately 5 mm
(radial and axial) for CRT 5 50 ps. In comparison,
for the CRT of approximately 500 ps, as presently
achieved by the uEXPLORER TB-PET, the PSF of
positronium image would equal to 30 mm (radial)
and 7 mm (axial).29
Fig. 4. Pictorial representation of the
basic processes involved in the “posi-
tronium tomography” using the
example of examination of the pros-
tate cancer. The PSMA-617 ligand)
labeled with radionuclide 44Sc attaches
to the PSMA receptors highly ex-
pressed in prostate epithelial cells.83
44Sc isotope emits positron (e1) and
prompt gamma (g) via following pro-
cess: 44Sc / 44Ca* e1 v / 44Ca g e1
v.44 Positron interacting with electrons
may form positronium atoms (indi-
cated as oPs or pPs) inside cell mole-
cules including intermolecular voids in
PSMA receptors as indicated in the
lower part of the sketch. Prompt
gamma may be detected in the tomo-
graph to give the signal approximately
the time of positronium formation. Ar-
rows indicate photons originating
from the annihilation of para- and
ortho-positronium inside free space
between atoms (magenta and orange
arrows), respectively. Black arrows indi-
cate annihilation of ortho-positronium
through the interaction with the elec-
tron from the surrounding molecule84
and green arrows illustrate photons
from the conversion of ortho-into
para-positronium via interaction with
the oxygen molecule82 and subsequent
decay of para-positronium to 2g.27
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use here the diagnosis of the prostate cancer.
Prostate-specific membrane antigen (PSMA),
(which is commonly used as a target for prostate
cancer imaging and treatment) is a nonsoluble
type 2 integral membrane protein with carboxy-
peptidase activity.101 PSMA is overexpressed in
prostate cancer cells, correlates to prostate-
specific antigen blood levels and reflects tumor
aggressiveness diagnosed both in tissue biopsies
and in prostate cancer imaging.102,103 In patients
having castration-resistant prostate cancer
metastasis, there is an unmet need to apply
imaging-guided prostate cancer therapy based
on total-body scanning and real-time theranos-
tics.104 For this purpose [44Sc]Sc-PSMA-617 for
PET imaging is the most suitable radiotracer68
(see Fig. 4). Application of [44Sc]Sc-PSMA-617
with TB-PET would enable an enhancement of ac-
curate diagnostics by simultaneous reconstruction
of the positronium image.Sensitivity of Multitracer and Positronium
Imaging with Total-Body PET Scanners
Multitracer imaging and mean lifetime positronium
imaging requires registration of triple coincidences
with 2 photons from e1e (Ps) / 2g annihilation
and prompt gamma emitted by the b1g isotope
as for example, 44Sc. Registration of the prompt
gamma enables a determination of the time of
the formation of positronium, and registration of
the correlated annihilation photons (2 or 3) allows
for the determination of the position and time of
the positronium annihilation.28,29,105,106 However,
the requirement of the registration and identifica-
tion of the prompt gamma, in addition to the 2
back-to-back annihilation photons, decreases
significantly the imaging sensitivity with respect
to the standard PET 2g imaging. Right panel of
Fig. 3 shows sensitivity gain calculated with
respect to the standard 2g metabolic imaging
with the 20 cm axial-length LYSO detector
Total-Body PET Imaging Using Plastic Scintillators 447indicated with the blue dot. The figure compares
results (dashed lines) for the sensitivity gain as a
function of the AFOV for multitracer and positro-
nium imaging (2g1prompt gamma) with respect
to the sensitivity gain for the standard SUV imag-
ing (solid lines). Results presented in the right
panel of Fig. 3 were obtained for Scandium
isotope as a b1g emitter, which is decaying via
the following reaction chain: 44Sc / 44Ca* e1 v
/ 44Ca g e1 v. Scandium was chosen as an
example because it is one of the most promising
b1g isotopes for medical applications due to (1)
its convenient half-lifetime (3.9 h), (2) emission of
only single prompt 1157 keV gamma with high
probability (99%), (3) short average time of prompt
gamma deexcitation (1.6 ps), (4) chemical affinity
enabling labeling of for example, DTPA and
DOTA-peptides which may be attached for
example, to trastuzumab-herceptin or PSMA
tracers, respectively, and (5) it possesses thera-
peutic partners (47Sc and 177Lu) emitting low-
energy electrons thus enabling theranostic
approach.44,107–109
Fig. 3 indicates that for the current standard PET
systems with 20 cm AFOV the (2g1prompt
gamma) sensitivity is by more than order of magni-
tude smaller with respect to the standard 2g SUV
imaging. However, with the increase of the AFOV
the sensitivity gain of positronium and multitracer
imaging increases strongly, and for the TB-PET
scanner, with AFOV of 200 cm, it exceeds the sen-
sitivities of the standard 2gmetabolic imaging with
the PET scanners with AFOV 5 20 cm by a factor
of approximately 7.5 in case of LYSO TB-PET and
by a factor of approximately 2.5 in case of the
plastic TB-J-PET scanner.SUMMARY AND PROSPECTS
The advent of TB-PET systems opens new possi-
bilities for the personalized medicine. Increase of
the AFOV to cover the total-body and the increase
of whole-body scan’s sensitivity by a factor of
approximately 40 enables simultaneous dynamic
imaging of all the organs, for the wider group of pa-
tients and diagnosis of systemic diseases.16
Recently uEXPLORER, the first TB-PET, demon-
strated kinetic and parametric imaging of all tis-
sues in the human body simultaneously.1,4,5
These new imaging capabilities deliver signifi-
cant quantitative improvements in diagnostic,
prognostic and theranostic assessments of
various oncological, cardiological, and neurologic
diseases.26 However, the extremely high cost of
the uEXPLORER prevents its dissemination in hos-
pitals and even in the research clinics. Therefore,
the widespread use of TB-PET systems in a wideclinical practice will be possible only after a drastic
reduction in the production cost of such
tomographs.
In this article, we have opined that the reduction
of crystal thickness or exchange of the LYSO by
BGO crystals will not lead to a significant enough
reduction of production costs, and as a solution
for the economic TB-PET we described the
concept of the TB-J-PET system using axially ar-
ranged long strips of plastic scintillators with
readout at the edges, instead of the typical detec-
tors built form radially arranged blocks of heavy
scintillator crystals.
Although the sensitivity increase expected for
the TB-PET built from plastic scintillators is by
approximately a factor of 2 lower with respect to
the TB-PET built from crystals, it is still significant
with respect to the current 20-cm to 25-cm-long
LYSO PET systems: factor of 27 for total-body im-
aging and factor of approximately 2 for single or-
gan imaging. Yet, the mechanical robustness of
plastics with respect to crystals enable to make
the plastic total-body scanner lightweight,
modular and portable. A photograph of the 24-
module prototype of such a scanner with 50 cm
AFOV is shown in the right panel of Fig. 2. Modu-
larity enables construction of PET with imaging
chamber adjustable to the size of the patient,
which could be of advantage in case of imaging
of for example, obese or claustrophobic patients.
Plastic TB-PET is a cost-effective solution for the
long axial FOV PET scanner. Total cost of compo-
nents of the plastic TB-PET is approximately 5
times less with respect to the crystal-based TB-
PET systems. Cost of crystal scintillators consti-
tutes approximately 50% of the total costs of the
TB-PET scanner.16 Plastic scintillators are more
than an order of magnitude less expensive than
LYSO crystals. Electronics and SiPMs constitute
another w50% of the costs of the crystal TB-
PET, and in case of plastic PET with axially
arranged scintillator strips these costs are signifi-
cantly reduced because the readout is placed
mainly at the ends of the cylindrical detector
compared with the coverage of the full cylinder
surface in case of the crystal PET detectors.
Thus in case of plastic TB-PET, the cost of elec-
tronics are proportional to the trans-axial cross-
section of the detector, whereas in case of crystal
TB-PET they are proportional to the area of the
detection cylinder. Overall the plastic TB-J-PET
may be more than factor of 5 less expensive
than the crystal-based TB-PET, making it a real-
istic cost-effective solution for the broad clinical
applications.
High sensitivity and long AFOV of TB-PET opens
new possibilities for diagnosis beyond the static
Moskal & Stępien448SUV index, improving diagnostic assessment
specificity by access to kinetic and parametric im-
aging of all organs of the patient, simulta-
neously.13,14 Then we presented examples of
further diagnostic benefits of TB-PET system that
arise from the possibility of effective multiphoton
imaging opening prospects for the multitracer
and positronium imaging and thus giving perspec-
tives for the further quantitative increase of the
diagnosis specificity. In the current PET imaging
the prompt gamma emitted by b1g isotopes as
for example, 44Sc constitutes a source of back-
ground. However, high sensitivity, triggerless
data acquisition36 and dedicated data selection
algorithms28,29,37,105,106,110,111 available at J-PET
enable efficient registration of triple coincidences
(see Fig. 3) corresponding to events with 2 back-
to-back annihilation photons and prompt gamma.
The additional information carried out by prompt
gammamay be used for (1) disentanglement of im-
ages from different radiopharmaceuticals in case
of simultaneous multitracer imaging,48 and for (2)
determination of the positronium mean lifetime
image.29
Assessing of tumor status using multiple PET
tracers has great potential for personalized
oncology.112 In clinical practice multitracer imag-
ing may decrease significantly the time needed
for the sequential imaging with more than 1 radio-
pharmaceutical that currently needs to be long be-
tween subsequent scans because of the long
(many hours) biological decay time needed for
cleaning up a tracer from the organism. Imaging
with 2 different tracers at once is currently imprac-
tical with standard 2g PET though it could enhance
significantly the diagnostic possibilities (for
example, by an early diagnostics of neuroendo-
crine and HER2 positive tumors) by delivering in-
formation of the tumor location (eg, from 18F
labeled radiopharmaceuticals) and simultaneously
independent information of the tumor type (cancer
receptor system) by use of for example, 44Sc-
DOTATATE radiopharmaceuticals, where DOTA-
TATE possesses high binding affinity for the
somatostatin receptors enhancing diagnostics
quality of neuroendocrine cancers.64 The scope
of applications of radiopharmaceuticals labeled
with Scandium (43Sc, 44Sc) is growing, particularly
for oncologic imaging purposes.64,113–116 Clinical
trials with 44Sc may be enhanced by the applica-
tion of TB-J-PET which in addition to SUV and ki-
netic parametric images would deliver positronium
lifetime image and may enable simultaneous
double-tracer imaging. Finally it is worth stressing
that a golden example of dual tracer analysis,
becoming possible with TB-J-PET, could be
a concurrent application of FDA-approved82Rb-Chloride and [18F]FDG, allowing simulta-
neous assessment of myocardium metabolic rate
and perfusion of the cardiovascular system.ACKNOWLEDGMENTS
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